RxDoctor Payments Data

Karina Patel, PA

Physician Assistant · Georgetown, TXNPI 1154006203

Payments from drug & device makers

$15,560in general payments, 2019–2025

Across 428 payments — averaging $36.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz Pharmaceuticals, LLC$4K
  • AbbVie$3K
  • Amneal Pharmaceuticals LLC$2K
  • Medtronic$2K
  • Abbott$1K
  • Teva Pharmaceuticals USA, Inc.$810
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$2,77918%
  • Travel & lodging$2,09313%
  • Food & beverage$10,55868%
  • Education$1291%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,560 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$14,462
Medicare patients
80
Services billed
195

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate66$410,152
RytaryCarbidopa/Levodopa149$264,425
AustedoDeutetrabenazine19$219,195
NourianzIstradefylline51$154,569
InbrijaLevodopa21$100,490
HorizantGabapentin Enacarbil37$56,693
OngentysOpicapone39$56,380
GocovriAmantadine Hcl17$38,145
NeuproRotigotine13$23,411
NuedextaDextromethorphan Hbr/Quinidine12$21,917
Carbidopa-Levodopa ErCarbidopa/Levodopa254$16,002
MyrbetriqMirabegron25$15,825
Carbidopa-LevodopaCarbidopa/Levodopa140$5,520
Droxidopa13$4,566
Midodrine Hcl53$4,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$609$410,15266 claims
Amneal Pharmaceuticals LLCRytary$1,875$264,425149 claims
Teva Pharmaceuticals USA, Inc.Austedo$810$219,19519 claims
Kyowa Kirin, Inc.Nourianz$274$154,56951 claims
Acorda Therapeutics, IncInbrija$62$100,49021 claims
Neurocrine Biosciences, Inc.Ongentys$636$56,38039 claims
MDD US Operations, LLCGocovri$322$38,14517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Georgetown

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →